ERAS
HEALTHCAREErasca Inc
Live · NASDAQ · May 9, Close
What's Moving ERAS Today?
No stock-specific AI insight has been generated for ERAS yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$10.90
Fundamentals
Trading
ERAS News
20 articles- Erasca Weighs ERAS-0015 Trial Progress Against Legal And Valuation QuestionsYahoo Finance·May 7, 2026
- Erasca to Present at the Bank of America Securities Health Care ConferenceYahoo Finance·May 6, 2026
- Erasca (ERAS) Announces Positive Preliminary Phase 1 Data for Pan-RAS Molecular Glue ERAS-0015Yahoo Finance·May 5, 2026
- Buy These 3 Clinical-Stage Biotechs Under $30 With Solid Cash Runways247 Wall St·May 4, 2026
- Revolution Medicines, Inc. (RVMD) One of the Best Stocks to Buy in a Rising Market amid $14B OpportunityYahoo Finance·May 2, 2026
- Erasca (ERAS) Recoups 16.9% Gain on Cancer Treatment OptimismYahoo Finance·May 1, 2026
- Why This CEO Is Confident His Drug Can Top 'Unprecedented' Pancreatic Cancer ResultsYahoo Finance·Apr 30, 2026
- Erasca Shares Plunge 48% After Trial Patient Death, Patent Dispute EmergesYahoo Finance·Apr 29, 2026
- Erasca stock sinks 50% after patient death in drug trialQz·Apr 29, 2026
- Patient Death Drags Erasca (ERAS) Shares by 48%Yahoo Finance·Apr 29, 2026
- Stock Market Today, April 28: Erasca Plunges After Patient Death in Early Cancer Drug TrialMotley Fool·Apr 28, 2026
- Erasca Stock Sinks 48% in Race for Pancreatic Cancer Miracle Drug. What’s Behind the Sell-Off.Yahoo Finance·Apr 28, 2026
- These Stocks Are Today’s Movers: Oracle, AMD, Intel, Corning, Centene, Erasca, Rambus, Coca-Cola, UPS, and MoreYahoo Finance·Apr 28, 2026
- Why Erasca, Up 415% This Year Amid Revolution-Tied Furor, Just Lost Half Its ValueYahoo Finance·Apr 28, 2026
- Erasca Shares Fall After Preliminary Phase 1 Dose Escalation DataYahoo Finance·Apr 28, 2026
- FDA claims Amgen drug data were ‘manipulated’; Erasca slides despite ‘home run’ resultsBiopharmadive·Apr 28, 2026
- Erasca Shares Phase 1 ERAS-0015 Data: 62% NSCLC Response, ctDNA Clearance SignalsMarketbeat·Apr 27, 2026
- Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid TumorsYahoo Finance·Apr 27, 2026
- Erasca to Host Conference Call and Webcast to Discuss Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015Yahoo Finance·Apr 27, 2026
- Erasca (ERAS) Hits 4-Year High Ahead of ERAS-0015 Trial ResultsYahoo Finance·Apr 21, 2026
All 20 articles loaded
Price Data
52-Week Range
$10.90
Fundamentals
Trading
About Erasca Inc
Erasca Inc. is an innovative biopharmaceutical company specializing in the development of targeted therapies for genetically defined cancers, addressing significant unmet medical needs within oncology. Leveraging its proprietary drug discovery platform that combines advanced genomics with precision medicine, Erasca focuses on creating therapies aimed at specific mutations that drive cancer progression. The company boasts a robust pipeline of clinical-stage candidates designed to disrupt key tumor growth pathways, enhancing treatment standards in cancer care. Erasca's dedication to improving patient outcomes is bolstered by strategic collaborations within the oncology research community, positioning it as a leader in the field.